|
‹³Žö |
’è@´’¼ |
•½¬‚P‚W”N‚P‚OŒŽ 〜 |
|
‹³Žö |
–Ø‘º@‹g‰„ |
º˜a‚T‚U”N‚SŒŽ 〜 •½¬‚P‚W”N‚RŒŽ |
|
•‹³Žö |
Œã“¡@•q |
•½¬@‚U”N‚SŒŽ 〜 •½¬‚P‚W”N‚RŒŽ |
|
•Žè |
¬¼@Fs |
•½¬Œ³”N‚P‚OŒŽ 〜 |
|
•Žè |
’|“à@Œ’Ži |
•½¬@‚R”N‚SŒŽ 〜 |
ƒAƒ_ƒvƒ^[’`”’Ž¿3BP2‚̶—“IE•a—“I–ðŠ„A‚¨‚æ‚ÑHCVŠ´õ‚̃VƒOƒiƒ‹“`’B‹@\‚ɂ‚¢‚Ă̌¤‹†
œ Œ¤‹†ŠT—v
“–—̈æ‚Å‚Í2006”N3ŒŽ‚É–Ø‘º‹g‰„‹³Žö‚ƌ㓡•q•‹³Žö‚ª‘ÞŠ¯‚µA“¯”N10ŒŽ‚ɒ肪Œã”C‹³Žö‚Æ‚µ‚Ä_ŒË‘åŠw‚æ‚è’…”C‚µV‚µ‚¢ƒXƒ^[ƒg‚ðØ‚Á‚½B2007”N2ŒŽ‚ɂ͉HŸâ•Žè‚ªV‚½‚ɉÁ‚í‚é—\’è‚Å‚ ‚éB
“–Œ¤‹†Žº‚ÌŽå—v‚ÈŒ¤‹†ƒe[ƒ}‚ÍA×–E“àƒVƒOƒiƒ‹“`’BA“Á‚ɃAƒ_ƒvƒ^[’`”’Ž¿‚ÉŠÖ‚·‚é‚à‚̂ł ‚éB
1. ƒAƒ_ƒvƒ^[’`”’Ž¿3BP2‚̶—“IE•a—“I–ðŠ„‚É‚Â‚¢‚Ă̌¤‹†@
ƒVƒOƒiƒ‹“`’B•ªŽq‚ÍA¶‘̂̈ێ‚⬒·‚É•s‰ÂŒ‡‚È”½‰ž‚ÉŠÖ‚í‚èA“Á’è‚©‚Âd—v‚È–ðŠ„‚ð’S‚Á‚Ä‚¢‚éBƒVƒOƒiƒ‹“`’B•ªŽq‚̈êŽí‚Å‚ ‚éƒAƒ_ƒvƒ^[’`”’Ž¿‚Í‘¼‚Ì•ªŽq‚Ɖ·‚邽‚߂̋@”\ƒhƒƒCƒ“‚ð—L‚·‚邪AŽ©‚ç‚Íy‘fŠˆ«‚ðŽ‚½‚È‚¢‚½‚ßA’P‚È‚éuŒq‚¬–ðv‚Ì•ªŽq‚Æ‚³‚ꂱ‚ê‚܂ł ‚Ü‚èd—vŽ‹‚³‚ê‚È‚©‚Á‚½B‚í‚ê‚í‚ê‚̓Aƒ_ƒvƒ^[’`”’Ž¿3BP2‚ª‚æ‚èϋɓI‚ɃVƒOƒiƒ‹“`’B‚ð’²ß‚µA×–E‰ž“š‚ɉe‹¿‚ð—^‚¦‚Ä‚¢‚邱‚Ƃ𖾂炩‚É‚µ‚Ä‚«‚½BƒAƒ_ƒvƒ^[’`”’Ž¿3BP2ˆâ“`Žq‚Ì“_“Ë‘R•ψق̓qƒgˆâ“`޾г‚̃Pƒ‹ƒrƒYƒ€Ç‚ðˆø‚«‹N‚±‚·‚±‚Æ‚ª•ñ‚³‚êA‚Ü‚½‰ºŠ{œ‚Ì”’B•s‘S‚Ƹ_’x‘؂𔺂¤Wolf-HirschhornÇŒóŒQ‚âäNã÷Šà‚É‚¨‚¢‚Ä‚à3BP2ˆâ“`Žq‚ªŒ‡Ž¸‚·‚éB‚í‚ê‚í‚ê‚ÍAŠù‚ɃPƒ‹ƒrƒYƒ€Œ^‚Ì3BP2‚ª‹@”\•s‘SŒ^‚ðŽ¦‚·‚±‚ƂȂNj»–¡[‚¢’mŒ©‚ð•ñ‚µ‚Ä‚¢‚éB¡Œã‚ÍAƒAƒ_ƒvƒ^[’`”’Ž¿3BP2‚̕ψقɂæ‚éƒPƒ‹ƒrƒYƒ€Ç‚̔ǂƕa‘Ԃɂ‚¢‚Ă̜–ƉuŠw“I‰ðÍ‚âA3BP2‚Æ•¡‡‘Ì‚ðŒ`¬‚·‚éŽó—e‘Ì’`”’Ž¿‚ɂ‚¢‚Ă̋@”\‰ðÍ‚ði‚߂Ă¢‚«‚½‚¢‚Æl‚¦‚Ä‚¢‚éB
2. CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXŠ´õ‚É‚æ‚éƒVƒOƒiƒ‹“`’B‹@\‚ɂ‚¢‚Ă̌¤‹†
CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXiHCVj‚ÍŠÌ‘Ÿ‚É–«‚̉ŠÇ‚ð‹N‚±‚µ‚—¦‚ÉŠÌ×–EŠà‚ðˆø‚«‹N‚±‚·‚ªA‚»‚Ì•ªŽq‹@˜‚ɂ‚¢‚Ă͕s–¾‚Ì“_‚ª‘½‚¢BŒ»ÝAHCVŠ´õ‚É‚æ‚éhŽå’`”’Ž¿‚Ì”Œ»‚Æ‹@”\A“Á‚É×–E“àƒVƒOƒiƒ‹“`’B‹@\‚ւ̉e‹¿‚ɂ‚¢‚Ä–Ô—…“I‚ɉðÍ‚ði‚߂Ă¢‚éB
‚»‚Ì‘¼A–Ø‘º‘O‹³Žö‚ÌRSƒEƒCƒ‹ƒXŠ´õ‚É‚æ‚é¶‘Ì–hŒä‹@\‚ÌŒ¤‹†‚âAŒã“¡•‹³Žö‚̃pƒ‰ƒ~ƒNƒ\ƒEƒCƒ‹ƒX‚É‚æ‚éƒCƒ“ƒ^[ƒtƒFƒƒ“’ïR«‚ÌŒ¤‹†‚ªˆê•”Œp‘±‚µ‚Äs‚í‚ꂽB‚Ü‚½–ƉuŠwEŠñ¶’ŽŠw‚̈ɕەŽè‚Ƃ̋¤“¯Œ¤‹†‚ªs‚í‚ꂽB
œ ƒL[ƒ[ƒh
¶‰»Šwˆê”Ê, ƒEƒCƒ‹ƒXŠw, ¶‘Ì–hŒä‚ƖƉuŒnˆê”Ê, ×–E“àƒVƒOƒiƒ‹“`’B, ƒAƒ_ƒvƒ^[’`”’Ž¿, ‚bŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX, ƒCƒ“ƒ^[ƒtƒFƒƒ“, ƒAƒŒƒ‹ƒM[
œ ‹ÆÑ”N‚Ìi’»ó‹µ
1. ƒAƒ_ƒvƒ^[’`”’Ž¿3BP2‚̶—“IE•a—“I–ðŠ„‚É‚Â‚¢‚Ă̌¤‹†@
3BP2‚ð‰î‚·‚é¶—ì—p‚Æ•a—ì—p‚̉ð͂Ɋւ·‚霖ƉuŒn‚ÌV‹KŽÀŒ±Œn‚Ì—§‚¿ã‚°‚ðs‚Á‚½B‚í‚ê‚í‚ê‚̓Aƒ_ƒvƒ^[’`”’Ž¿‚ɂ‚¢‚Ă̌¤‹†‚̈ꕪ–ì‚Æ‚µ‚ÄAƒAƒ_ƒvƒ^[—l‹@”\‚ð—L‚·‚é’`”’Ž¿ƒ†ƒrƒLƒ`ƒ“ƒŠƒK[ƒ[A“Á‚ÉCbl‚ɂ‚¢‚Ă̌¤‹†‚ÉŽæ‚è‘g‚ñ‚Å‚¨‚èA–{”N‚Í—‰»ŠwŒ¤‹†Š‚Æ“Œ‹ž–ò‰È‘åŠw‚Ƃ̋¤“¯Œ¤‹†‚É‚æ‚èAƒ~ƒgƒRƒ“ƒhƒŠƒA‚É”Œ»‚·‚éV‹Kƒ†ƒrƒLƒ`ƒ“ƒŠƒK[ƒ[‚𓯒肵Aƒ~ƒgƒRƒ“ƒhƒŠƒA‹@”\‚ð§Œä‚·‚邱‚Æ‚ð•ñ‚µ‚½B
2. CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXŠ´õ‚É‚æ‚éƒVƒOƒiƒ‹“`’B‹@\‚ɂ‚¢‚Ă̌¤‹†
HCVƒQƒmƒ€—R—ˆ‚Ì’`”’Ž¿‚Í‘½Ê‚È•a—ì—p‚ð—L‚·‚éB–{”N‚ÍAHCVƒEƒCƒ‹ƒX’`”’Ž¿NS3ANS4A‚É‚æ‚éhŽå’`”’Ž¿‚Ƃ̉Ɗà”Ç‹@\‚ւ̉e‹¿‚ɂ‚¢‚ĉðÍ‚ðs‚¢ANS3‚ÆŠà—}§ˆâ“`ŽqŽY•¨p53‚Ƃ̉̕ªŽqƒƒJƒjƒYƒ€‚Æ—}§‹@˜‚âANS4A‚É‚æ‚éƒ~ƒgƒRƒ“ƒhƒŠƒA‹@”\‚ւ̉e‹¿‚ɂ‚¢‚Ä•ñ‚ðs‚Á‚½BÅ‹ßA‘SƒQƒmƒ€‚ªŽ©—¥‘B‚·‚éHCV RNAƒŒƒvƒŠƒRƒ“Œn‚âHCVŠ´õŒn‚ªŠm—§‚³‚êA–«CŒ^ŠÌ‰Š‚É‚¨‚¯‚éŠà”Ç‹@\‚̈ê‚‚Ƃµ‚ÄAŠà—}§ˆâ“`ŽqŽY•¨‚Å‚ ‚é”ñŽó—e‘ÌŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[Syk‚Ƃ̊֌W‚ɂ‚¢‚Ä’²‚ׂ½‚Æ‚±‚ëASyk‚ªNS5A‚ɉµA‚»‚ÌŠˆ«‚ð—}§‚·‚邱‚Ƃ𖾂炩‚É‚µ‚½BHCV’`”’Ž¿‚Ì”Œ»‚É‚æ‚èŠÌ×–EŠà‚ª”Ç‚·‚郃JƒjƒYƒ€‚̈ê‚‚Ƃµ‚ÄAƒ`ƒƒVƒ“ƒLƒi[ƒ[‚ð‰î‚·‚éƒVƒOƒiƒ‹“`’B‹@\‚Ì”j’]‚ªl‚¦‚ç‚ê‚éi“Še’†jB‚³‚ç‚É–«CŒ^ŠÌ‰Š‚ɇ•¹‚·‚铜”A•a‚̔ǃƒJƒjƒYƒ€‚ɂ‚¢‚ĉðÍ‚µAHCV‚ªGLUT2AGLUT1‚Ì×–E–Œ•\–ʂւ̔Œ»—}§‚ð‰î‚µ‚ăOƒ‹ƒR[ƒXŽæ‚螂݂ð—}§‚·‚邱‚Æ‚ðŒ©o‚µ‚½i“Še’†jBŒö“IŒ¤‹†”ï‚Æ‚µ‚ÄC
‰ÈŠwŒ¤‹†”ï•â•‹àEŠî”ÕŒ¤‹†i‚bju‚bŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX’`”’Ž¿‚É‚æ‚éŠÌ×–E‚Ì’`”’Ž¿ƒ`ƒƒVƒ“ƒŠƒ“Ž_‰»”½‰ž‚ւ̉e‹¿viŒ¤‹†‘ã•\ŽÒ@’è´’¼j‚ðŽó‚¯‚½B
œ “ÁF“™
1. ‚í‚ê‚í‚ê‚ÍA]—ˆuŒq‚¬–ðv‚Æ‚µ‚Ä‘¨‚¦‚ç‚ê‚Ä‚¢‚½ƒAƒ_ƒvƒ^[’`”’Ž¿‚É‚æ‚éϋɓI‚È×–E‰ž“š‚ÌŽd‘g‚݂ɂ‚¢‚Ä–¾‚ç‚©‚É‚µ‚Ä‚«‚½B3BP2‚ªƒ}ƒXƒg×–E‚É”Œ»‚µAIgE‚ð‰î‚·‚éƒAƒŒƒ‹ƒM[‰ž“š‚ð³‚ɧŒä‚·‚邱‚Æ‚ðŒ©o‚µ‚½B‚Ü‚½3BP2‚̃mƒbƒNƒAƒEƒgƒ}ƒEƒX‚Ì•\Œ»Œ^‚ª•ñ‚³‚ê‚邿‚è‚à‚©‚È‚è‘O‚ÉAsiRNA‚ð—p‚¢‚ÄƒŠƒ“ƒp‹…Šˆ«‰»ƒVƒOƒiƒ‹‚É‚¨‚¯‚é•K‘R“I‚È–ðŠ„‚ð–¾‚ç‚©‚É‚µ‚½B‚±‚ê‚ç‚̓Ƒn“I‚È•ñ‚Í2006”N‚ÉCellŽ‚âNature
ImmunologyŽAAnnual Review of ImmunologyŽã‚ňø—p‚³‚êA‚í‚ê‚í‚ê‚ÌŒ¤‹†¬‰Ê‚ªƒAƒ_ƒvƒ^[’`”’Ž¿‚É‚æ‚é×–E‰ž“š‚̧Œä‹@\‚Ì—‰ð‚É‹‚¢‰e‹¿‚ð—^‚¦‚±‚Æ‚ðŽ¦‚µ‚Ä‚¢‚éBŒ»ÝƒAƒ_ƒvƒ^[’`”’Ž¿3BP2‚ÌŒ¤‹†‚ł͢ŠE‚ÌÅæ’[‚ð‘–‚Á‚Ä‚¢‚邱‚Æ‚ðŽ©•‰‚µ‚Ä‚¢‚éB‚í‚ê‚í‚ê‚ÌŒ¤‹†‚ÍA3BP2‚̈â“`ŽqˆÙí‚É‚æ‚éƒqƒg‚̈â“`޾гƒPƒ‹ƒrƒYƒ€‚̔ǃƒJƒjƒYƒ€‰ð–¾A‚³‚ç‚ɂ͊֘A‚·‚éŽ¾Š³‚ÌŽ¡—Ö@ŠJ”‚ȂǗlX‚È”“W«‚ð—L‚·‚邯l‚¦‚ç‚ê‚éB
‹¤“¯Œ¤‹†‚̬‰Ê‚Æ‚µ‚Ä•ñ‚µ‚½ƒ~ƒgƒRƒ“ƒhƒŠƒA‚̃†ƒrƒLƒ`ƒ“ƒŠƒK[ƒ[‚ɂ‚¢‚Ă̌¤‹†‚ÍA”ñí‚É‚‚¢…€‚ÌŽGނɔ•\‚µ‚½iEMBO
JOurnal, IF: 10.086jB
2. –{”N‚Ì”•\˜_•¶‚̂Ȃ©‚Å‚ÍHCVƒEƒCƒ‹ƒX’`”’Ž¿‚É‚æ‚éhŽå’`”’Ž¿‚Æ‚Ì‘ŠŒÝì—p‚Æ•aŒ´«A‚·‚Ȃ킿ŠÌ×–EŠà”ǃƒJƒjƒYƒ€‚ւ̉e‹¿‚̉𖾂ª“Á•M‚³‚ê‚éB]—ˆAHCV‚ÌŒ¤‹†‚ł͎©—¥‚µ‚ăEƒCƒ‹ƒX—±Žq‚ª‘B‚Å‚«‚éƒVƒXƒeƒ€‚ª¢ŠE‚ÅŒ©‚‚©‚Á‚Ä‚¢‚È‚©‚Á‚½‚½‚ß‚ÉAHCV
repliconƒVƒXƒeƒ€‚ª‘㊷ƒVƒXƒeƒ€‚Æ‚µ‚Ä—p‚¢‚ç‚ê‚Ä‚«‚½B‚±‚ê‚ÍHCVƒQƒmƒ€‚ðˆê•”‘€ì‚µ‚½RNA‚ð×–E‚É“±“ü‚·‚邯AƒQƒmƒ€‚ª•¡»‚³‚ê‚邪AƒEƒCƒ‹ƒX—±Žq‚ÍŽY¶‚³‚ê‚È‚¢ƒVƒXƒeƒ€‚Å‚ ‚éB‚±‚ÌŽd‘g‚Ý‚ÆAŠeƒEƒCƒ‹ƒX’`”’Ž¿‚ðŒÂ•ʂɔŒ»‚³‚¹‚é•û–@‚𕹗p‚·‚邱‚Ƃɂæ‚èA‚±‚ê‚܂Ŗ¾‚ç‚©‚É‚³‚ê‚Ä‚±‚È‚©‚Á‚½HCV‚Ì”ñ\‘¢’`”’Ž¿‚É‚æ‚éŠà—}§’`”’Ž¿p53‚Ì‹@”\‚ð—}§‚·‚éŒø‰Ê‚Æ•ªŽqƒƒJƒjƒYƒ€‚𖾂炩‚É‚µ‚½‚±‚Ƃ͓Á•M‚É’l‚·‚éB‚³‚ç‚É‚²‚Å‹ßA‘S‚V‚µ‚¢HCVŠ´õŽÀŒ±Œn‚ª“oꂵA‚í‚ê‚í‚ê‚à‚¢‚¿‘‚‚»‚̃VƒXƒeƒ€‚𓱓ü‚µ‚ÄA‚±‚ê‚܂Œm‚ç‚ê‚邱‚Ƃ̂Ȃ©‚Á‚½’`”’Ž¿ƒ`ƒƒVƒ“ƒŠƒ“Ž_‰»”½‰ž‚ւ̉e‹¿‚ɂ‚¢‚͉»Šw“IŒ©’n‚©‚猟“¢‚ð‰Á‚¦‚Ä‚¢‚邱‚Æ‚à‘å‚«‚È“ÁF‚Å‚ ‚éBHCV‚Ì•aŒ´«”Œ»‹@\‚ÉŠÖ‚·‚邱‚ê‚ç‚ÌŒ¤‹†¬‰Ê‚Í‚¢‚¸‚ê‚à‘n–ò‚ÌŠÏ“_‚©‚甓W«‚ð—L‚·‚é‚à‚̂ƈʒu•t‚¯‚ç‚ê‚éB
œ –{Šw‚Ì—”O‚Ƃ̊֌W
d“_“IŒ¤‹†•ª–ì‚̂ЂƂ‚ł ‚éA–Ɖu‚ÉŠÖ‚·‚邎Ÿ¶‘̃VƒXƒeƒ€‚Ì\’z‚âˆÛŽ‚É‚Â‚¢‚Ă̕ªŽqƒƒJƒjƒYƒ€‚̉ð͂ɂ‚¢‚ÄA‚í‚ê‚í‚ê‚ÌŽ‚¶‰»Šw‚ƃEƒCƒ‹ƒXŠw‚Æ‚¢‚¤ˆÙ‚È‚éƒoƒbƒNƒOƒ‰ƒEƒ“ƒh‚ð¶‚©‚µA‘¼‘åŠwEŒ¤‹†Š‚Ƃ̋¤“¯Œ¤‹†‚ð’Ê‚¶‚ÄA“–ŠY•ª–ì‚É‚¨‚¯‚颊E…€‚ÌŒ¤‹†¬‰Ê‚ð‹“‚°‚½‚Æl‚¦‚ç‚ê‚éB¡Œã‚Í«—ˆ‚ÌŒ¤‹†‚ð’S‚¤lވ笂ɂàϋɓI‚ÉŠÖ‚í‚Á‚Ä‚¢‚«‚½‚¢B
|
‹æ@@•ª |
•Ò@@” |
ƒCƒ“ƒpƒNƒgƒtƒ@ƒNƒ^[ (‚¤‚¿Œ´’˜‚Ì‚Ý) |
|||
|
2001`2006”N•ª |
2006”N•ª |
2001`2006”N•ª |
2006”N•ª |
||
|
˜a•¶Œ´’˜˜_•¶ |
0 |
0 |
\\\\\ |
\\\\\ |
|
|
‰p•¶˜_•¶ |
̧°½Äµ°»° |
34 |
0 |
104.410 ( 104.410) |
0.000 ( 0.000) |
|
ºÚ½ÎßÝÃިݸ޵°»° |
33 |
0 |
102.101 ( 102.101) |
0.000 ( 0.000) |
|
|
‚»‚Ì‘¼ |
7 |
7 |
26.396 ( 26.396) |
26.396 ( 26.396) |
|
|
‡Œv |
41 |
7 |
130.806 ( 130.806) |
26.396 ( 26.396) |
|
iAj ’˜‘E˜_•¶“™
(1)
‰p•¶F˜_•¶“™
aDŒ´’˜˜_•¶iR¸—Lj
0622001
+M.Tanaka, +M.Nagano-Fujii, +L.Deng, +S.Ishido, K.Sada,
+H.Hotta: Single-point mutations of hepatitis C virus NS3 that impair
p53 interaction and anti-apoptotic activity of NS3. Biochem Biophys Res Commun,
340i3j, 792-799, 2006.02, #2.855
0622002
+L.Deng, +M.Nagano-Fujii, +M.Tanaka,
+Y.Nomura-Takigawa, +M.Ikeda, +N.Kato, K.Sada, +H.Hotta: The NS3 protein
of hepatitis C virus associates with the tumor suppressor p53 and inhibits its
function in an NS3 sequence-dependent manner. J Gen Virol, 87i6j,
1703-1713, 2006.06, #3.110
0622003
+H.Hotta, +K.Nihei, +Y.Abe, +S.Kato, +D.P.Jiang,
+M.Nagano-Fujii, K.Sada: Full-length sequence analysis of subacute sclerosing
panencephalitis (SSPE) virus, a mutant of measles virus, isolated from brain
tissues of a patient shortly after onset of SSPE. Microbiol Immunol, 50i7j, 525-534,
2006.07, #1.502
0622004
+Y.Nomura-Takigawa, +M.Nagano-Fujii, +L.Deng,
+S.Kitazawa, +S.Ishido, K.Sada, +H.Hotta: The nonstructural protein 4A
of hepatitis C virus accumulates on mitochondria and induces apoptotic cell
death through a mitochondria-mediated pathway. J Gen Virol, 87i7j,
1935-1945, 2006.07, #3.110
0622005
+M.Otaki, K.Sada, +H.Kadoya, +M.Nagano-Fujii, +H.Hotta:
Inhibition of measles virus and subacute sclerosing panencephalitis virus by
RNA interference. Antiviral Res, 70i3j, 105-111,
2006.07, #2.878
0622006
+R.Yonashiro, +S.Ishido, +S.Kyo, +T.Fukuda, +E.Goto,
+Y.Matsuki, +M.Ohmura-Hashimoto, K.Sada, +H.Hotta, +H.Yamamura, +R.Inatome, +S.Yanagi:
A novel mitochondria ubiquitin ligase plays a critical role in mitochondrial
dynamics. EMBO J, 25i15j, 3618-3626, 2006.08,
#10.086
0622007
+K.Tsuji-Naito, T.Hatani, +T.Okada, +T.Tehara: Evidence for
covalent lipoyl adduction with dopaquinone following tyrosinase-catalyzed
oxidation. Biochem Biophys Res Commun, 343i1j, 15-20,
2006, #2.855
(2)
˜a•¶F˜_•¶“™
bD‘à
(0522028)
’è@´’¼: ƒ}ƒXƒg×–EŠˆ«‰»ƒVƒOƒiƒ‹‚ð§Œä‚·‚镪Žq. Molecular
Medicine, 42i10j, 1107-1112, 2005
(0522029)
’è@´’¼: ”ì–ž×–E‚É‚¨‚¯‚éFcepsilonƒŒƒZƒvƒ^[I‚©‚ç‚̃VƒOƒiƒ‹“`’BF3BP2‚ÆCbl-b‚É‚æ‚é”ì–ž×–EŠˆ«‰»§Œä. —Õ°–Ɖu, 44i1j, 63-70,
2005
iBj Šw‰ï”•\“™
(1) ‘ÛŠw‰ï
aDˆê”Êu‰‰iƒ|ƒXƒ^[j
(0522030)
+Y.Nomura-Takigawa,
+H.Hotta, +M.Nagano-Fujii, +L.Deng, +S.Kitazawa, +S.Ishido, K.Sada: The
nonstructural protein 4A of hepatitis C virus accumulates on mitochondria and
induces apoptotic cell death through the mitochondria-mediated pathway, 12th
International Symposium on Hepatitis C Virus and Related Viruses, 2005,
Montréal(Canada), Abstract, 121, 2005
(0522031)
+M.Nagano-Fujii,
+S.Inubushi, +H.Mizuta, +M.Tanaka, +H.Yamamura, K.Sada, +K.Hotta: The
nonstructural protein 5A of hepatitis C virus associates with and negatively
regulates the enzymatic activity of non-receptor tyrosine kinase Syk in Huh-7
cells, 12th International Symposium on Hepatitis C Virus and Related Viruses,
2005, Montréal(Canada), Abstract, 132, 2005
0622008
+S.Inubushi,
+M.Nagano-Fujii, +C.An, +K.Kitayama, +H.Yokozaki, +H.Yamamura, +M.Ikeda,
+N.Kato, K.Sada, +H.Hotta: Hepatitis C virus NS5A protein associates with and
negatively regulates a non-receptor protein-tyrosine kinase Syk in Huh-7 cells,
The 20th IUBMB International Congress of Biochemistry and Molecular Biology,
2006.06, Kyoto(Japan), Abstract, 206, 2006
0622009
K.Takeuchi, T.Komatsu,
+B.Gotoh: Blockage of PKR activation in Sendai virus infected cells: Involvement
of the viral C gene, The 20th IUBMB International Congress of Biochemistry and
Molecular Biology, 2006.06, ‹ž“sŽs
0622010
+A.El-Shamy,
+M.Sasayama, +M.Nagano-Fujii, K.Sada, +S.R.Kim, +H.Hotta: A high degree of
sequence variation of HCV NS5A and the presence of anti-NS5A antibodies in the
pretreatment sera are associated with efficient viral clearance by combination
therapy using pegylated interferon and ribavirin, 13th International Symposium
on Hepatitis C Virus and Related Viruses, 2006.08, Sydney(Australia), Abstract,
63, 2006.08
0622011
K.Sada, +H.Yamamura,
+H.Hotta: Regulation of IgE-mediated mast cell activation by 3BP2 and Cbl-b.,
International symposium of
0622012
+S.Inubushi,
+M.Nagano-Fujii, +K.Kitayama, +H.Yamamura, K.Sada, +H.Hotta: Kinase activity of
the non-receptor tyrosine kinase Syk is down-regulated in Huh-7.5 cells
harboring an HCV RNA subgenomic replicon, 13th International Symposium on
Hepatitis C Virus and Related Viruses, 2006, Sydney(Australia), Abstract, 129,
2006
(2) ‘“àŠw‰ïi‘S‘ƒŒƒxƒ‹j
aDƒVƒ“ƒ|ƒWƒXƒgEƒpƒlƒŠƒXƒg“™
0622013
+–x“c@”Ž, +’·–ì@ŠîŽq, ’è@´’¼: CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX”ñ\‘¢’`”’Ž¿NS3‚ÆNS4A‚Ì×–E•Ï«ì—p‚Æ×–E‚ª‚ñ‰»‚Ö‚ÌŠÖ—^, ‘æ10‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘å‰ïE“ú–{ŠÌ‘ŸŠw‰ï, 2006.10, ŽD–y, u‰‰—vŽ|, A308,
2006
bDˆê”Êu‰‰iŒû‰‰j
(0522032)
+’·–ì@ŠîŽq, +Œ¢•š@ËŽq, +“c’†@Šî•¶, +ˆÀ@t‰p, +–쑺@—º‘¾, +X“c@‰Á“ÞŽq, ’è@´’¼, +–x“c@”Ž: CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXNS5A‚Í”ñŽó—e‘ÌŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[Syk‚ɉµ‚»‚̃Lƒi[ƒ[Šˆ«‚𕉂ɧŒä‚·‚é, ‘æ53‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2005, ‰¡•l, ´˜^W, 198, 2005
0622014
+’·–ì@ŠîŽq, +Ahmed El
Shamy, +‹à@Žç—Ç, +ˆä–{@•×, +•w–Ø@Gˆê, +‹à@Œ[“ñ, +’JŒû@”üK, ’è@´’¼, +–x“c@”Ž: –«CŒ^ŠÌ‰Š‚ɑ΂·‚éƒyƒOƒCƒ“ƒ^[ƒtƒFƒƒ“/ƒŠƒoƒrƒŠƒ“•¹—p—Ö@‚Ì‘ŠúŽ¡—ÃŒø‰Ê‚ÆCŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXNS5A‚ÌV3—̈æƒAƒ~ƒmŽ_”z—ñ‘½—l«‚Ì‘ŠŠÖ‚É‚Â‚¢‚Ä, ‘æ42‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ïE“ú–{ŠÌ‘ŸŠw‰ï, 2006.05, ‹ž“s, u‰‰—vŽ|, A116,
2006
0622015
+Œã“¡•q, ¬¼@Fs, ’|“à@Œ’Ži, +–kì‘P‹I: ƒqƒgƒƒ^ƒjƒ…[ƒ‚ƒEƒCƒ‹ƒX‚ƃCƒ“ƒ^[ƒtƒFƒƒ“’ïR”\, ‘æ54‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ï, 2006.11, –¼ŒÃ‰®Žs
cDˆê”Êu‰‰iƒ|ƒXƒ^[j
(0522033)
+‘å‘ë@“Žq, +’·–ì@ŠîŽq, +Šp–î@”Ž•Û, +‰Á“¡@½ˆê, +‘ëì@—L‹I, ’è@´’¼, +–x“c@”Ž: siRNA‚É‚æ‚éSSPEƒEƒCƒ‹ƒX‘B—}§–@ŠJ”‚ÌŠî‘b“IŒŸ“¢, ‘æ53‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2005, ‰¡•l, ´˜^W, 243, 2005
(0522034)
+Maria Inge Lusida, +’·–ì@ŠîŽq, +X“c@‰Á“ÞŽq, +ùŽR@”ü‹IŽq, ’è@´’¼, +–x“c@”Ž: ƒCƒ“ƒhƒlƒVƒA‚Ì‚aŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX‚Ìgenotype‰ð͂ƃEƒCƒ‹ƒXi‰»‚ÌlŽ@, ‘æ53‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2005, ‰¡•l, ´˜^W, 296, 2005
(0522035)
+‰Á“¡@½ˆê, +’·–ì@ŠîŽq, +‘å‘ë@“Žq, +î–{@^Ž¡, ’è@´’¼, +–x“c@”Ž: ˆŸ‹}«d‰»«‘S”]‰Š(SSPE)”nj㑊ú‚É•ª—£‚µ‚½SSPEƒEƒCƒ‹ƒX‚̃Qƒmƒ€\‘¢‚ƃEƒCƒ‹ƒX«ó‚̉ðÍ, ‘æ53‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2005, ‰¡•l, ´˜^W, 319, 2005
0622016
+‹à@Žç—Ç, +ˆä–{@•×, +’JŒû@”üK, +‹à@Œ[“ñ, +’·–ì@ŠîŽq, ’è@´’¼, +–x“c@”Ž: PEG-IFN+ƒŠƒoƒrƒŠƒ“•¹—p—Ö@‚ÌŒø‰Ê—\‘ª‚É‚¨‚¯‚é2f-5fƒIƒŠƒSƒAƒfƒjƒŒƒCƒg‡¬y‘f(2-5AS)‚̉ž“š«‚ÌŒŸ“¢, ‘æ42‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ïE“ú–{ŠÌ‘ŸŠw‰ï, 2006.05, ‹ž“s, u‰‰—vŽ|, A218,
2006
0622017
+‹à@Žç—Ç, +ˆä–{@•×, +–x“c@”Ž, +’JŒû@”üK, +‹à@Œ[“ñ, +’·–ì@ŠîŽq, ’è@´’¼: PEG-IFN+ƒŠƒoƒrƒŠƒ“•¹—p—Ö@‚ÌŽ¡—ÃŒø‰Ê—\‘ª‚É‚¨‚¯‚éƒEƒCƒ‹ƒXdynamics‚ÌŒŸ“¢, ‘æ42‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ïE“ú–{ŠÌ‘ŸŠw‰ï, 2006.05, ‹ž“s, u‰‰—vŽ|, A221,
2006
0622018
+’·–ì@ŠîŽq, +–x“c@”Ž, +Ahmed El
Shamy, ’è@´’¼, +‹à@Žç—Ç, +ˆä–{@•×, +•w–Ø@Gˆê, +‹à@Œ[“ñ, +’JŒû@”üK: ƒyƒOƒCƒ“ƒ^[ƒtƒFƒƒ“^ƒŠƒoƒrƒŠƒ“•¹—p—Ö@–³Œø—á‚ÆHCV NS5A‚ÌV3—̈æƒAƒ~ƒmŽ_”z—ñ‘½—l«‹y‚ÑNS5AR‘̗̂L–³‚Æ‚Ì‘ŠŠÖ, ‘æ10‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘å‰ïE“ú–{ŠÌ‘ŸŠw‰ï, 2006.10, ŽD–y, u‰‰—vŽ|, A400,
2006
0622019
+Ahmed El Shamy, +ùŽR@”ü‹IŽq, +’·–ì@ŠîŽq, +‹à@Žç—Ç, ’è@´’¼, +–x“c@”Ž: CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXNS5A‚̃Aƒ~ƒmŽ_”z—ñ‘½—l«‹y‚ÑŒŒ’†NS5AR‘̗̂L–³‚ƃyƒOƒCƒ“ƒ^[ƒtƒFƒƒ“^ƒŠƒoƒrƒŠƒ“•¹—p—Ö@‘ŠúŽ¡—ÃŒø‰Ê‚Æ‚Ì‘ŠŠÖ‚É‚Â‚¢‚Ä, ‘æ54‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2006.11, –¼ŒÃ‰®, ´˜^W, 269, 2006
0622020
+Œ¢•š@ËŽq, +’·–ì@ŠîŽq, +–kŽR@Šì‹v”ü, ’è@´’¼, +–x“c@”Ž: CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXŠ´õ‚ª”ñŽó—e‘ÌŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[Syk‚É‹y‚Ú‚·‰e‹¿, ‘æ54‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2006.11, –¼ŒÃ‰®, ´˜^W, 259, 2006
0622021
¬¼@Fs, ’|“à@Œ’Ži, +Œã“¡•q: RSƒEƒCƒ‹ƒX‚̃Cƒ“ƒ^[ƒtƒFƒƒ“ƒAƒ“ƒ^ƒSƒjƒYƒ€, ‘æ54‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ï, 2006.11, –¼ŒÃ‰®Žs
0622022
’|“à@Œ’Ži, ¬¼@Fs, +Œã“¡•q: ƒZƒ“ƒ_ƒCƒEƒCƒ‹ƒX‚ÌIFN’ïR«F‘æŽO‚Ì‹@\, ‘æ54‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ï, 2006.11, –¼ŒÃ‰®Žs
(3) ‘“àŠw‰ïi’nˆæƒŒƒxƒ‹j
aDˆê”Êu‰‰iŒû‰‰j
0622023
¬¼@Fs: ƒqƒgRSƒEƒCƒ‹ƒX‚̃Cƒ“ƒ^[ƒtƒFƒƒ“‘ÎR”\, ‘æ43‰ñ“ú–{׋ۊw‰ï’†•”Žx•”‘‰ï, 2006.10
bDˆê”Êu‰‰iƒ|ƒXƒ^[j
0622024
+Ahmed El Shamy, +ùŽR@”ü‹IŽq, +’·–ì@ŠîŽq, +‹à@Žç—Ç, ’è@´’¼, +–x“c@”Ž: –«CŒ^ŠÌ‰Š‚ɑ΂·‚éƒyƒOƒCƒ“ƒ^[ƒtƒFƒƒ“^ƒŠƒoƒrƒŠƒ“•¹—p—Ö@‘ŠúŽ¡—ÃŒø‰Ê‚ÆNS5A‚̃Aƒ~ƒmŽ_”z—ñ‘½—l«‚¨‚æ‚ÑŒŒ’†NS5AR‘̗̂L–³‚Æ‚Ì‘ŠŠÖ, ‘æ59‰ñ“ú–{׋ۊw‰ïŠÖ¼Žx•”‘‰ïE“ú–{׋ۊw‰ïŠÖ¼Žx•”, 2006.10, ‚’Î, —\eW, 45, 2006
iCj ‚»‚Ì‘¼‹ÆÑ
|
·
’è@´’¼: ƒtƒ‰ƒ“ƒX‘—§‰q¶ˆãŠwŒ¤‹†ŠEƒtƒ‰ƒ“ƒX“ï•aŒ¤‹†ŠŠO•”•]‰¿ˆõ, 2006.04` |
|
‹æ•ª |
Œ¤‹†Ží–Ú |
‰Û@‘è@–¼ |
‘ã•\ŽÒ–¼ |
•ª’SŽÒ–¼ |
Šú@ŠÔ i”N“xj |
‹à@Šz i”z•ªŠzj |
|
•¶•”‰ÈŠwȉȊw Œ¤‹†”ï•â•‹à |
Šî”ÕŒ¤‹†(C)ˆê”Ê |
CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX’`”’Ž¿‚É‚æ‚éŠÌ×–E‚Ì’`”’Ž¿ƒ`ƒƒVƒ“ƒŠƒ“Ž_‰»”½‰ž‚ւ̉e‹¿ |
’è@´’¼ |
|
2006 |
2,700ç‰~ |
|
•¶•”‰ÈŠwȉȊw Œ¤‹†”ï•â•‹à |
Šî”ÕŒ¤‹†(C)ˆê”Ê |
ƒqƒgƒƒ^ƒjƒ…[ƒ‚ƒEƒCƒ‹ƒX‚Ì•aŒ´«‚ƃCƒ“ƒ^[ƒtƒFƒƒ“ƒAƒ“ƒ^ƒSƒjƒYƒ€ |
Œã“¡@•q |
|
2006 |
1,800ç‰~ |
|
Šw“à‹£‘ˆ“IŽ‘‹à |
Šw’·Ù—ÊŒo”ïEŠî‘b“IE–G‰è“IŒ¤‹† |
–ƉuŽhŒƒƒIƒŠƒSDNA palGACGA0901‚̃AƒŒƒ‹ƒM[EƒEƒBƒ‹ƒXŠ´õŽ¡—Âւ̉ž—p |
*ˆÉ•Û@ŸŽq |
’|“àŒ’Ži |
2006 |
600ç‰~ |
|
Šw“à‹£‘ˆ“IŽ‘‹à |
‹£‘ˆ“I”z•ªŒo”ïEŒ¤‹† |
Œ`Ž¿×–E—lŽ÷ó×–E‚ÌŠˆ«‰»‚Æ‚»‚̧Œä‹@\‚̉ðÍ |
*ˆÉ•Û@ŸŽq |
’|“à@Œ’Ži, ¬¼@Fs |
2006 |
500ç‰~ |
iBj §ŠwŠñ•‹à
|
Žó“üŒ” |
1@Œ |
|
Žó“ü‹àŠz |
91,206@‰~ |
iAj ‘E’nˆæ“™‚Ö‚ÌvŒ£
(1) R‹c‰ïEˆÏˆõ‰ïEŒö‰v–@lE‰ïŽÐ“™‚Ö‚ÌŽQ‰Áó‹µ
|
‹æ•ª |
‹@ŠÖEˆÏˆõ‰ï‚Ì–¼Ì“™ |
–ðE |
Ž–¼ |
ŠúŠÔ |
|
’n•ûީޡ‘Ì |
•ŸˆäŒ§, •ŸˆäŒ§Œ‹ŠjEŠ´õÇ—\–h‘ÎôˆÏˆõ‰ï |
ˆÏˆõ |
–Ø‘º@‹g‰„ |
2003.02` |
|
’n•ûީޡ‘Ì |
•ŸˆäŒ§‰q¶ŠÂ‹«ƒZƒ“ƒ^[Œ¤‹†‰Û‘è•]‰¿ˆÏˆõ‰ï |
ˆÏˆõ |
–Ø‘º@‹g‰„ |
2003.08` |
|
’n•ûީޡ‘Ì |
•ŸˆäŒ§‰q¶ŠÂ‹«¾ÝÀ°, Œ¤‹†‰Û‘è•]‰¿ˆÏˆõ‰ï |
ˆÏˆõ |
–Ø‘º@‹g‰„ |
2005.08` |
|
‚»‚Ì‘¼ |
•ŸˆäŒ§, •ŸˆäŒ§Œ‹ŠjEŠ´õÇ—\–h‘ÎôˆÏˆõ‰ï |
ˆÏˆõ |
–Ø‘º@‹g‰„ |
2005.01` |
(2) ŽÐ‰ïl“™‚Ö‚ÌvŒ£‹y‚ÑŠwZ“™‚Ƃ̘AŒgE‹¦—͂ɂæ‚銈“®
|
‹æ•ª |
Šˆ“®–¼EŠˆ“®“à—e |
ŽåÃŽÒE‘ÎÛŽÒ“™ |
Ž–¼ |
|
‚»‚Ì‘¼ |
SPP, ”÷¶•¨Šw‚ւ̵‘Ò |
‚Z¶ |
’è@´’¼ |
iBj ‚»‚Ì‘¼‹ÆÑ
|
·
–Ø‘º@‹g‰„: Clinical Infectious Diseases, R¸ˆÏˆõ,
2005` |